Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

Literature DB >> 9641517

Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

H Ogasawara¹, M Sekiya, A Murashima, T Hishikawa, Y Tokano, I Sekigawa, N Iida, H Hashimoto, S Hirose.

Abstract

Cyclosporin is known to be effective for both transplantation and a spectrum of immune-mediated diseases. Because this agent also causes severe adverse effects, especially nephrotoxicity, careful monitoring is required for the development of such reactions. Here we report the successful treatment with extremely low-dose cyclosporin (1 mg/kg/day) of a patient who had steroid-resistant interstitial pneumonitis and Sjögren's syndrome.

Entities: Chemical Disease Species

Mesh：

Substances：
Cyclosporine

Year: 1998 PMID： 9641517 DOI： 10.1007/bf01452266

Source DB: PubMed Journal: Clin Rheumatol ISSN： 0770-3198 Impact factor: 2.980

22 in total

1. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

Authors: P Tugwell; C Bombardier; M Gent; K J Bennett; W G Bensen; S Carette; A Chalmers; J M Esdaile; A V Klinkhoff; G R Kraag
Journal: Lancet Date: 1990-05-05 Impact factor: 79.321

2. Cyclosporin blood levels do correlate with clinical complications.

Authors: E Irschik; H Tilg; D Niederwieser; G Gastl; C Huber; R Margreiter
Journal: Lancet Date: 1984-09-22 Impact factor: 79.321

Review 3. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.

Authors: W B Gruhn; J A Diaz-Buxo
Journal: J Rheumatol Date: 1987-10 Impact factor: 4.666

4. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.

Authors: A Bacigalupo; M T Van Lint; D Occhini; F Gualandi; T Lamparelli; G Sogno; E Tedone; F Frassoni; J Tong; A M Marmont
Journal: Blood Date: 1991-04-01 Impact factor: 22.113

5. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?

Authors: A R Mueller; K P Platz; G Blumhardt; W O Bechstein; T Steinmüller; W Christe; U Hopf; H Lobeck; P Neuhaus
Journal: Clin Transplant Date: 1995-06 Impact factor: 2.863

6. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens.

Authors: A Lindholm; S Ohlman; D Albrechtsen; G Tufveson; H Persson; N H Persson
Journal: Transplantation Date: 1993-08 Impact factor: 4.939

1. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.

Authors: Claudia Kedor; Jan Zernicke; Anja Hagemann; Lorena Martinez Gamboa; Johanna Callhoff; Gerd-Rüdiger Burmester; Eugen Feist
Journal: Clin Rheumatol Date: 2016-07-28 Impact factor: 2.980

1 in total

Very low-dose cyclosporin treatment of steroid-resistant interstitial pneumonitis associated with Sjögren's syndrome.

1. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

2. Cyclosporin blood levels do correlate with clinical complications.

Review 3. Cyclosporine treatment of steroid resistant interstitial pneumonitis associated with dermatomyositis/polymyositis.

4. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.

5. The optimal immunosuppressant after liver transplantation according to diagnosis: cyclosporine A or FK506?

6. The impact of acute rejection episodes on long-term graft function and outcome in 1347 primary renal transplants treated by 3 cyclosporine regimens.

7. Labial salivary gland biopsy in Sjögren's syndrome. Assessment as a diagnostic criterion in 362 suspected cases.

8. Chronic nephrotoxicity in psoriatic patients treated with low-dose cyclosporine.

9. Cyclosporine in psoriasis: a multicenter dose-finding study in severe plaque psoriasis. The German Multicenter Study.

10. Low-dose short-term cyclosporine versus etretinate in psoriasis: improvement of skin, nail, and joint involvement.

1. A phase II investigator-initiated pilot study with low-dose cyclosporine A for the treatment of articular involvement in primary Sjögren's syndrome.